These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 17620589

  • 1. Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia.
    Larson JS, Bergstrom LK, Cameron JD, Erickson LA, Grimm TE.
    Arch Ophthalmol; 2007 Jul; 125(7):985-6. PubMed ID: 17620589
    [No Abstract] [Full Text] [Related]

  • 2. Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia.
    Ramar K, Potti A, Mehdi SA.
    J Clin Oncol; 2003 Jan 01; 21(1):172-3. PubMed ID: 12506189
    [No Abstract] [Full Text] [Related]

  • 3. Severe periorbital edema secondary to STI571 (Gleevec).
    Esmaeli B, Prieto VG, Butler CE, Kim SK, Ahmadi MA, Kantarjian HM, Talpaz M.
    Cancer; 2002 Aug 15; 95(4):881-7. PubMed ID: 12209733
    [Abstract] [Full Text] [Related]

  • 4. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Defuentes G, Bladé JS, Berets O.
    N Engl J Med; 2007 Oct 11; 357(15):1556-7; author reply 1557-8. PubMed ID: 17928609
    [No Abstract] [Full Text] [Related]

  • 5. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Schiffer CA.
    N Engl J Med; 2007 Jul 19; 357(3):258-65. PubMed ID: 17634461
    [No Abstract] [Full Text] [Related]

  • 6. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
    Breccia M, Gentilini F, Cannella L, Latagliata R, Carmosino I, Frustaci A, Alimena G.
    Leuk Res; 2008 Jul 19; 32(7):1022-5. PubMed ID: 18061664
    [Abstract] [Full Text] [Related]

  • 7. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA, Junaid A, Siddiqui NS, Mukhtar K, Siddiqui S.
    J Coll Physicians Surg Pak; 2008 Mar 19; 18(3):176-8. PubMed ID: 18460249
    [Abstract] [Full Text] [Related]

  • 8. Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib.
    Bajel A, Bassili S, Seymour JF.
    Leuk Res; 2008 Nov 19; 32(11):1789-90. PubMed ID: 18462793
    [No Abstract] [Full Text] [Related]

  • 9. Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia.
    O'Dwyer ME, Druker BJ.
    Curr Opin Oncol; 2000 Nov 19; 12(6):594-7. PubMed ID: 11085460
    [Abstract] [Full Text] [Related]

  • 10. A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
    Sausville EA.
    J Natl Cancer Inst; 1999 Jan 20; 91(2):102-3. PubMed ID: 9923844
    [No Abstract] [Full Text] [Related]

  • 11. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec 01; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract] [Full Text] [Related]

  • 12. Oral BMS-354825 rescues Gleevec-resistant CML.
    Cancer Biol Ther; 2004 Aug 01; 3(8):700. PubMed ID: 15751154
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Oral and maxillofacial pathology case of the month. Palatal melanosis associated with imatinib mesylate therapy.
    Yu YH, Shere Y, Vigneswaran N.
    Tex Dent J; 2012 Aug 01; 129(8):764-5, 786-8. PubMed ID: 22988661
    [No Abstract] [Full Text] [Related]

  • 15. Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia.
    Anzalone CL, Cohen PR, Kurzrock R, Cortes JE.
    Dermatol Online J; 2014 Jan 15; 20(1):21242. PubMed ID: 24456946
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
    Saito M, Izumiyama K, Mori A, Irie T, Tanaka M, Morioka M, Saga A, Musashi M, Kato T, Meguro T, Tanino M.
    Rinsho Ketsueki; 2014 Jan 15; 55(1):130-2. PubMed ID: 24492046
    [Abstract] [Full Text] [Related]

  • 18. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 19. [Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy].
    Sumi M, Tauchi T, Shimamoto T, Sshida G, Nakajima A, Ito Y, Ohyashiki K.
    Rinsho Ketsueki; 2002 Sep 01; 43(9):868-70. PubMed ID: 12412295
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.